Literature DB >> 22422994

Treating human autoimmunity: current practice and future prospects.

Michael D Rosenblum1, Iris K Gratz, Jonathan S Paw, Abul K Abbas.   

Abstract

Autoimmune diseases are caused by immune cells attacking the host tissues they are supposed to protect. Recent advances suggest that maintaining a balance of effector and regulatory immune function is critical for avoiding autoimmunity. New therapies, including costimulation blockade, regulatory T cell therapy, antigen-specific immunotherapy, and manipulating the interleukin-2 pathway, attempt to restore this balance. This review discusses these advances as well as the challenges that must be overcome to target these therapies to patients suffering from autoimmune disease while avoiding the pitfalls of general immunosuppression.

Entities:  

Mesh:

Year:  2012        PMID: 22422994      PMCID: PMC4061980          DOI: 10.1126/scitranslmed.3003504

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  65 in total

1.  Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes.

Authors:  J Bathon; M Robles; A C Ximenes; S Nayiager; J Wollenhaupt; P Durez; J Gomez-Reino; W Grassi; B Haraoui; W Shergy; S-H Park; H Genant; C Peterfy; J-C Becker; A Covucci; D Moniz Reed; R Helfrick; R Westhovens
Journal:  Ann Rheum Dis       Date:  2011-08-06       Impact factor: 19.103

2.  Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells.

Authors:  Daniel R Getts; Danielle M Turley; Cassandra E Smith; Christopher T Harp; Derrick McCarthy; Emma M Feeney; Meghann Teague Getts; Aaron J Martin; Xunrong Luo; Rachael L Terry; Nicholas J C King; Stephen D Miller
Journal:  J Immunol       Date:  2011-08-05       Impact factor: 5.422

Review 3.  Opposing functions of IL-2 and IL-7 in the regulation of immune responses.

Authors:  Shoshana D Katzman; Katrina K Hoyer; Hans Dooms; Iris K Gratz; Michael D Rosenblum; Jonathan S Paw; Sara H Isakson; Abul K Abbas
Journal:  Cytokine       Date:  2011-07-31       Impact factor: 3.861

Review 4.  Mechanisms of immunotherapy to wasp and bee venom.

Authors:  C Ozdemir; U C Kucuksezer; M Akdis; C A Akdis
Journal:  Clin Exp Allergy       Date:  2011-07-05       Impact factor: 5.018

Review 5.  Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis.

Authors:  Mark M Davis; John D Altman; Evan W Newell
Journal:  Nat Rev Immunol       Date:  2011-07-15       Impact factor: 53.106

6.  Regulatory T cells: stability revisited.

Authors:  Samantha L Bailey-Bucktrout; Jeffrey A Bluestone
Journal:  Trends Immunol       Date:  2011-05-27       Impact factor: 16.687

7.  Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.

Authors:  Diane K Wherrett; Brian Bundy; Dorothy J Becker; Linda A DiMeglio; Stephen E Gitelman; Robin Goland; Peter A Gottlieb; Carla J Greenbaum; Kevan C Herold; Jennifer B Marks; Roshanak Monzavi; Antoinette Moran; Tihamer Orban; Jerry P Palmer; Philip Raskin; Henry Rodriguez; Desmond Schatz; Darrell M Wilson; Jeffrey P Krischer; Jay S Skyler
Journal:  Lancet       Date:  2011-06-27       Impact factor: 79.321

8.  Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.

Authors:  Tihamer Orban; Brian Bundy; Dorothy J Becker; Linda A DiMeglio; Stephen E Gitelman; Robin Goland; Peter A Gottlieb; Carla J Greenbaum; Jennifer B Marks; Roshanak Monzavi; Antoinette Moran; Philip Raskin; Henry Rodriguez; William E Russell; Desmond Schatz; Diane Wherrett; Darrell M Wilson; Jeffrey P Krischer; Jay S Skyler
Journal:  Lancet       Date:  2011-06-28       Impact factor: 79.321

Review 9.  Immune intervention in type 1 diabetes.

Authors:  Aaron W Michels; George S Eisenbarth
Journal:  Semin Immunol       Date:  2011-08-17       Impact factor: 11.130

10.  In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy.

Authors:  Chao-Lien Liu; Peiqing Ye; Benjamin C Yen; Carol H Miao
Journal:  Mol Ther       Date:  2011-04-05       Impact factor: 11.454

View more
  58 in total

1.  Dead on arrival: understanding the failure of CTLA4-immunoglobulin therapy in inflammatory bowel disease.

Authors:  Lloyd Mayer; Arthur Kaser; Richard S Blumberg
Journal:  Gastroenterology       Date:  2012-05-21       Impact factor: 22.682

Review 2.  The Gut Microbiota and the Emergence of Autoimmunity: Relevance to Major Psychiatric Disorders.

Authors:  Emily G Severance; Dag Tveiten; Lief H Lindström; Robert H Yolken; Karl L Reichelt
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

3.  Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region.

Authors:  Maura Rossetti; Roberto Spreafico; Suzan Saidin; Camillus Chua; Maryam Moshref; Jing Yao Leong; York Kiat Tan; Julian Thumboo; Jorg van Loosdregt; Salvatore Albani
Journal:  J Immunol       Date:  2014-12-01       Impact factor: 5.422

4.  Interleukin-2 treatment reverses effects of cAMP-responsive element modulator α-over-expressing T cells in autoimmune-prone mice.

Authors:  K Ohl; A Wiener; A Schippers; N Wagner; K Tenbrock
Journal:  Clin Exp Immunol       Date:  2015-05-14       Impact factor: 4.330

5.  An autoantibody identifies arrhythmogenic right ventricular cardiomyopathy and participates in its pathogenesis.

Authors:  Diptendu Chatterjee; Meena Fatah; Deniz Akdis; Danna A Spears; Tamara T Koopmann; Kirti Mittal; Muhammad A Rafiq; Bruce M Cattanach; Qili Zhao; Jeff S Healey; Michael J Ackerman; Johan Martijn Bos; Yu Sun; Jason T Maynes; Corinna Brunckhorst; Argelia Medeiros-Domingo; Firat Duru; Ardan M Saguner; Robert M Hamilton
Journal:  Eur Heart J       Date:  2018-11-21       Impact factor: 29.983

6.  Convergent and divergent effects of costimulatory molecules in conventional and regulatory CD4+ T cells.

Authors:  Ei Wakamatsu; Diane Mathis; Christophe Benoist
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-31       Impact factor: 11.205

7.  Memory regulatory T cells reside in human skin.

Authors:  Robert Sanchez Rodriguez; Mariela L Pauli; Isaac M Neuhaus; Siegrid S Yu; Sarah T Arron; Hobart W Harris; Sara Hsin-Yi Yang; Bryan A Anthony; Francis M Sverdrup; Elisabeth Krow-Lucal; Tippi C MacKenzie; David S Johnson; Everett H Meyer; Andrea Löhr; Andro Hsu; John Koo; Wilson Liao; Rishu Gupta; Maya G Debbaneh; Daniel Butler; Monica Huynh; Ethan C Levin; Argentina Leon; William Y Hoffman; Mary H McGrath; Michael D Alvarado; Connor H Ludwig; Hong-An Truong; Megan M Maurano; Iris K Gratz; Abul K Abbas; Michael D Rosenblum
Journal:  J Clin Invest       Date:  2014-02-10       Impact factor: 14.808

8.  Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo.

Authors:  David A Horwitz; Stephanie Pan; Jing-Ni Ou; Julie Wang; Maogen Chen; J Dixon Gray; Song Guo Zheng
Journal:  Clin Immunol       Date:  2013-08-20       Impact factor: 3.969

9.  Elevated levels of IL-23 in a subset of patients with post-lyme disease symptoms following erythema migrans.

Authors:  Klemen Strle; Daša Stupica; Elise E Drouin; Allen C Steere; Franc Strle
Journal:  Clin Infect Dis       Date:  2013-11-11       Impact factor: 9.079

Review 10.  Engineering Immune Tolerance with Biomaterials.

Authors:  Joshua M Gammon; Christopher M Jewell
Journal:  Adv Healthc Mater       Date:  2019-01-03       Impact factor: 9.933

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.